Cerebellopontine angle meningiomas: LINAC stereotactic radiosurgery treatment

Isabel M. Ortiz García , Ana M. Jorques Infante , Nicolás Cordero Tous , Julio Almansa López , José Expósito Hernández , Gonzalo Olivares Granados
{"title":"Cerebellopontine angle meningiomas: LINAC stereotactic radiosurgery treatment","authors":"Isabel M. Ortiz García ,&nbsp;Ana M. Jorques Infante ,&nbsp;Nicolás Cordero Tous ,&nbsp;Julio Almansa López ,&nbsp;José Expósito Hernández ,&nbsp;Gonzalo Olivares Granados","doi":"10.1016/j.neucie.2023.02.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><p><span><span>To evaluate the efficacy of treatment with linear accelerator-based </span>stereotactic radiosurgery (LINAC) in </span>cerebellopontine angle meningiomas.</p></div><div><h3>Methods</h3><p>We analyzed 80 patients diagnosed with cerebellopontine angle meningiomas between 2001 and 2014, treated with stereotactic radiosurgery (SRS), of whom 81.9% (n<!--> <!-->=<!--> <!-->68) were women, with an average age of 59.1 years (32–79). SRS was applied as primary treatment in 83.7% (n<!--> <!-->=<!--> <!-->67) and in 16.3% (n<!--> <!-->=<!--> <!-->13) as an adjuvant treatment to surgery. SRS treatment was provided using LINAC (Varian 600, 6<!--> <!-->MeV) with M3 micromultilamines (brainLab) and stereotactic frame. The average tumor volume was 3.12<!--> <!-->cm<sup>3</sup> (0.34–10.36<!--> <!-->cm<sup>3</sup>) and the coverage dose was 14<!--> <!-->Gy (12–16<!--> <span><span>Gy). We performed a retrospective descriptive analysis and survival analysis was performed with the Kaplan–Meier method and multivariate analysis to determine those </span>factors predictive of tumor progression or clinical improvement.</span></p></div><div><h3>Results</h3><p>After an average follow-up period of 86.9 months (12–184), the tumor control rate was 92.8% (n<!--> <!-->=<!--> <!-->77). At the end of the study, there was an overall reduction in tumor volume of 32.8%, with an average final volume of 2.11<!--> <!-->cm<sup>3</sup> (0–10.35<!--> <!-->cm<sup>3</sup>). The progression-free survival rate at 5, 10 and 12 years was 98%, 95% and 83.3% respectively. The higher tumor volume (<em>p</em> <!-->=<!--> <!-->0.047) was associated with progression. There was clinical improvement in 26.5% (n<!--> <!-->=<!--> <!-->21) of cases and clinical worsening in 16.2% (n<!--> <!-->=<!--> <span>13). Worsening is related to the radiation dose received by the brainstem (</span><em>p</em> <!-->=<!--> <span><span>0.02). Complications were 8.7% (7 cases) of hearing loss, 5% (4 cases) of brain radionecrosis, and 3.7% (3 cases) of cranial nerve V </span>neuropathy. Hearing loss was related to initial tumor size (</span><em>p</em> <!-->=<!--> <!-->0.033) and maximum dose (<em>p</em> <!-->=<!--> <!-->0.037). The occurrence of radionecrosis with the maximum dose (<em>p</em> <!-->=<!--> <!-->0.037).</p></div><div><h3>Conclusions</h3><p>Treatment of cerebellopontine angle meningiomas with single-dose SRS using LINAC is effective in the long term. Better tumor control rates were obtained in patients with small lesions.</p></div>","PeriodicalId":74273,"journal":{"name":"Neurocirugia (English Edition)","volume":"34 6","pages":"Pages 283-291"},"PeriodicalIF":0.0000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurocirugia (English Edition)","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2529849623000084","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives

To evaluate the efficacy of treatment with linear accelerator-based stereotactic radiosurgery (LINAC) in cerebellopontine angle meningiomas.

Methods

We analyzed 80 patients diagnosed with cerebellopontine angle meningiomas between 2001 and 2014, treated with stereotactic radiosurgery (SRS), of whom 81.9% (n = 68) were women, with an average age of 59.1 years (32–79). SRS was applied as primary treatment in 83.7% (n = 67) and in 16.3% (n = 13) as an adjuvant treatment to surgery. SRS treatment was provided using LINAC (Varian 600, 6 MeV) with M3 micromultilamines (brainLab) and stereotactic frame. The average tumor volume was 3.12 cm3 (0.34–10.36 cm3) and the coverage dose was 14 Gy (12–16 Gy). We performed a retrospective descriptive analysis and survival analysis was performed with the Kaplan–Meier method and multivariate analysis to determine those factors predictive of tumor progression or clinical improvement.

Results

After an average follow-up period of 86.9 months (12–184), the tumor control rate was 92.8% (n = 77). At the end of the study, there was an overall reduction in tumor volume of 32.8%, with an average final volume of 2.11 cm3 (0–10.35 cm3). The progression-free survival rate at 5, 10 and 12 years was 98%, 95% and 83.3% respectively. The higher tumor volume (p = 0.047) was associated with progression. There was clinical improvement in 26.5% (n = 21) of cases and clinical worsening in 16.2% (n = 13). Worsening is related to the radiation dose received by the brainstem (p = 0.02). Complications were 8.7% (7 cases) of hearing loss, 5% (4 cases) of brain radionecrosis, and 3.7% (3 cases) of cranial nerve V neuropathy. Hearing loss was related to initial tumor size (p = 0.033) and maximum dose (p = 0.037). The occurrence of radionecrosis with the maximum dose (p = 0.037).

Conclusions

Treatment of cerebellopontine angle meningiomas with single-dose SRS using LINAC is effective in the long term. Better tumor control rates were obtained in patients with small lesions.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
桥小脑角脑膜瘤:LINAC立体定向放射外科治疗。
目的:评价基于直线加速器的立体定向放射外科(LINAC)治疗桥小脑角脑膜瘤的疗效。方法:我们分析了2001年至2014年间诊断为桥小脑角脑膜瘤并接受立体定向放射外科治疗的80例患者,其中81.9%(n=68)为女性,平均年龄59.1岁(32-79岁)。83.7%(n=67)将SRS作为主要治疗,16.3%(n=13)将其作为手术辅助治疗。SRS治疗是使用具有M3微多层(brainLab)和立体定向框架的LINAC(Varian 600,6MeV)提供的。平均肿瘤体积为3.12cm3(0.34-10.36cm3),覆盖剂量为14Gy(12-16Gy)。我们进行了回顾性描述性分析,并使用Kaplan-Meier方法和多变量分析进行了生存率分析,以确定那些预测肿瘤进展或临床改善的因素。结果:平均随访86.9个月(12-184),肿瘤控制率为92.8%(n=77)。研究结束时,肿瘤体积总体减少了32.8%,平均最终体积为2.11cm3(0-10.35cm3)。5年、10年和12年的无进展生存率分别为98%、95%和83.3%。较高的肿瘤体积(p=0.047)与进展有关。26.5%(n=21)的病例有临床改善,16.2%(n=13)的病例临床恶化。病情恶化与脑干接受的辐射剂量有关(p=0.02)。并发症包括8.7%(7例)的听力损失、5%(4例)的脑放射性坏死和3.7%(3例)的颅神经V神经病。听力损失与肿瘤的初始大小(p=0.033)和最大剂量(p=0.037)有关。最大剂量下放射性坏死的发生率(p=0.027)。结论:LINAC单剂量SRS治疗桥小脑角脑膜瘤是长期有效的。小病变患者的肿瘤控制率较高。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Association of the C-reactive protein/albumin ratio with the prognosis of Aneurysmal Subarachnoid Hemorrhage: A systematic review. Moyamoya disease and moyamoya syndrome: A case series from multicentre private hospitals in Indonesia. Trigeminal neuralgia secondary to minor size lesion, anatomical considerations and pathophysiology. Utility of very high-pressure valves in persistent symptomatic shunt overdrainage. Idiopathic normal pressure hydrocephalus: A critical analysis of its underrepresentation across Italian medical-scientific societies in the last 5 years.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1